Attached files
| file | filename |
|---|---|
| 8-K - FORM 8-K - Oncotelic Therapeutics, Inc. | d571887d8k.htm |
Exhibit 3.1
CERTIFICATE OF AMENDMENT TO
RESTATED CERTIFICATE OF INCORPORATION OF
OXiGENE, INC.
It is hereby certified that:
| FIRST: | The name of the corporation is OXiGENE, Inc. (the “Corporation”). | |
| SECOND: | The Restated Certificate of Incorporation of the Corporation, as amended to date, is hereby further amended by striking out Section A of Article Fourth in its entirety and by substituting in lieu thereof the following: | |
| “A. Designation and Number of Shares. | ||
| The aggregate number of shares of all classes of stock which the Corporation is authorized to issue is Eighty Five Million (85,000,000) shares, of which Seventy Million (70,000,000) shares are designated Common Stock, of the par value of One Cent ($0.01) per share, and Fifteen Million (15,000,000) shares are designated Preferred Stock, of the par value of One Cent ($0.01) per share.” | ||
| THIRD: | The amendment of the Restated Certificate of Incorporation herein certified has been duly adopted in accordance with the provisions of Section 242 of the General Corporation Law of the State of Delaware. | |
EXECUTED, effective as of this 17th day of July, 2013.
| OXiGENE, Inc. | ||
| By: | /s/ Peter J. Langecker | |
| Peter J. Langecker, M.D., Ph.D. | ||
| Chief Executive Officer | ||